Trending NewsTrending NewsMost-Upgraded StocksMost-UpgradedNASDAQ:MRNA Moderna (MRNA) Stock Price, News & Analysis $200.10 -2.53 (-1.25%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$201.35 +1.25 (+0.62%) As of 10/23/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Moderna Stock (NASDAQ:MRNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Moderna alerts:Sign Up Key Stats Today's Range$183.00▼$206.9750-Day Range$62.96▼$245.8152-Week Range$22.28▼$254.48Volume21.51 million shsAverage Volume19.46 million shsMarket Capitalization$79.89 billionP/E RatioN/ADividend YieldN/APrice Target$103.95Consensus RatingHold Company Overview Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas. Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The company also maintains a pipeline of investigational vaccines and therapeutics, including programs targeting seasonal influenza, cytomegalovirus, combination respiratory infections and cancer-related applications. Founded in 2010 and originally known as ModeRNA Therapeutics, Moderna is headquartered in Cambridge, Massachusetts. The company serves markets internationally through regulatory approvals, commercial partnerships and distribution arrangements. Stéphane Bancel has served as Moderna’s chief executive officer, while Noubar Afeyan is the company’s founder and chairman.AI Generated. May Contain Errors. Read More Moderna Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreMRNA MarketRank™: 2.08411591092 of 5 starsModerna scored higher than 42% of companies evaluated by MarketBeat, and ranked 643rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingModerna has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on no strong buy ratings, 7 buy ratings, 14 hold ratings, and 4 sell ratings.Downside RiskModerna has a consensus price target of $103.95, representing about 48.1% downside from its current price of $200.10.Amount of Analyst CoverageModerna has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Moderna's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moderna are expected to grow in the coming year, from ($6.11) to ($4.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moderna is -25.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moderna is -25.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioModerna has a P/B Ratio of 9.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Moderna's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.67% of the float of Moderna has been sold short.Short Interest Ratio / Days to CoverModerna has a short interest ratio ("days to cover") of 1.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moderna has recently decreased by 6.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldModerna does not currently pay a dividend.Dividend GrowthModerna does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.01 News SentimentModerna has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 81 news articles for Moderna this week, compared to 8 articles on an average week.Search Interest80 people have searched for MRNA on MarketBeat in the last 30 days. This is an increase of 105% compared to the previous 30 days.MarketBeat Follows52 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 53% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,875,904.00 in company stock.Percentage Held by Insiders10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Moderna's insider trading history. Receive MRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRNA Stock News HeadlinesModerna (MRNA) Stock May Be Fully Priced As Melanoma Vaccine Data Leaks48 minutes ago | finance.yahoo.comModerna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy TranscriptOctober 24 at 7:24 PM | seekingalpha.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 25 at 1:00 AM | Porter & Company (Ad)Moderna: Why Positive Phase 3 Results Weren't EnoughOctober 24 at 2:31 PM | seekingalpha.comModerna investors should brace for more whiplashOctober 24 at 9:23 AM | msn.comBreakfast News: A Conversation With Moderna's CEOOctober 24 at 9:00 AM | fool.comThe AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning (MRNA)AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.October 19, 2026 | marketbeat.comInsider Selling: Moderna (NASDAQ:MRNA) President Sells $8,373,539.52 in StockOctober 17, 2026 | insidertrades.comSee More Headlines MRNA Stock Analysis - Frequently Asked Questions How have MRNA shares performed this year? Moderna's stock was trading at $29.49 at the beginning of the year. Since then, MRNA shares have increased by 578.5% and is now trading at $200.10. How were Moderna's earnings last quarter? Moderna, Inc. (NASDAQ:MRNA) posted its quarterly earnings data on Friday, July, 31st. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. Moderna's quarterly revenue was up 2.1% compared to the same quarter last year. Read the conference call transcript. When did Moderna IPO? Moderna (MRNA) raised $604 million in an initial public offering on Friday, December 7th 2018. The company issued 26,275,993 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. Who are Moderna's major shareholders? Moderna's top institutional shareholders include Banque Pictet & Cie SA (0.54%), Douglas Lane & Associates LLC (0.29%), Beau Ventures LLc (0.25%) and TD Waterhouse Canada Inc. (0.02%). Insiders that own company stock include Stephen Hoge, Shannon Thyme Klinger, James M Mock, Abbas Hussain, Noubar Afeyan and Arpa Garay. View institutional ownership trends. How do I buy shares of Moderna? Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moderna own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), NIO (NIO), Alibaba Group (BABA) and PayPal (PYPL). Company Calendar Last Earnings7/31/2026Today10/25/2026Next Earnings (Estimated)11/06/2026Investor Day 202611/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MRNA's financial health is in the Green zone, according to TradeSmith. MRNA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MRNA CIK1682852 Webwww.modernatx.com Phone(617) 714-6500FaxN/AEmployees4,700Year Founded2010Price Target and Rating Average Price Target for Moderna$103.95 High Price Target$200.00 Low Price Target$17.00 Potential Upside/Downside-48.1%Consensus RatingHold Rating Score (0-4)2.12 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($7.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.82 billion Net Margins-141.43% Pretax Margin-138.55% Return on Equity-28.30% Return on Assets-19.39% Debt Debt-to-Equity Ratio0.09 Current Ratio2.29 Quick Ratio2.18 Sales & Book Value Annual Sales$1.94 billion Price / Sales41.09 Cash FlowN/A Price / Cash FlowN/A Book Value$22.14 per share Price / Book9.04Miscellaneous Outstanding Shares399,240,000Free Float356,119,000Market Cap$79.89 billion OptionableOptionable Beta1.09 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MRNA) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
